Aegon Ltd. (AEG) Stock Price & How to Invest

Aegon Ltd is a life insurance and retirement group whose center of gravity has shifted almost entirely to the United States. The dominant business is Transamerica, which sells individual life insurance, annuities, workplace retirement plans and mutual funds, and distributes much of that through World Financial Group, an agent network that passed 95,000 licensed agents during 2025. Outside the US, the group runs a UK workplace pensions and adviser platform, a joint venture with Santander across Spain and Portugal, an interest in Mongeral Aegon in Brazil, and an asset management arm. The company sold its Dutch insurance operations to a.s.r. in 2023 and has been steadily simplifying what remains. Roughly 15,300 people work there, and the reporting currency is still the euro even though the earnings are overwhelmingly dollar-denominated.

The investment picture is a capital-return case wrapped around a corporate reorganization. Full-year 2025 brought an operating result of about EUR 1.7 billion (up 15 percent), operating capital generation of about EUR 1.3 billion against a EUR 1.2 billion target, and a net result of roughly EUR 980 million. Management returned about EUR 1.1 billion through dividends and buybacks and guided the 2025 to 2027 transition period toward roughly 5 percent annual growth in the operating result and free cash flow, with dividend growth above 5 percent a year from a base of about EUR 0.40 per share. In May 2026 Aegon reached an agreement with Vereniging Aegon, its long-standing anchor shareholder, and published a US-aligned governance proposal; shareholders are expected to vote on redomiciliation at an extraordinary meeting in the fourth quarter of 2026, with the holding company scheduled to be renamed Transamerica Inc. by January 1, 2028. The shares have roughly doubled off their 52-week low and still change hands near 9 to 10 times forward earnings, which tells you the market is pricing the legacy American life liabilities, not the growth.

The legacy American book is the reason the multiple is low: Transamerica carries long-term care and older universal life liabilities whose reserve adequacy depends on morbidity, mortality, lapse and claim-cost assumptions that get revisited annually, and an adverse review can wipe out a year of earnings growth in one press release. Earnings and capital are sensitive to interest rates, credit spreads and equity markets at the same time, so a credit cycle that hits the fixed income portfolio while equity-linked fee income falls would pressure both sides. The redomiciliation is not finished: it needs a shareholder vote expected in the fourth quarter of 2026, regulatory clearance, and a transition of the group's capital framework from Bermuda and Solvency II toward US-style supervision, and any of those can slip. Reporting stays in euros while cash flows are mostly dollars, so translation adds noise that has nothing to do with underlying performance. Rate competition in annuities from well-capitalized private-credit-backed rivals can also compress spreads faster than the company's own repricing cycle.

We give no verdict on Aegon Ltd.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Becoming an American company on paper, not just in practice. Aegon has picked Delaware for its legal seat, New York City for a headquarters opening around mid-2027, and January 1, 2028 as the date the holding company becomes Transamerica Inc.

The case against. The legacy American book is the reason the multiple is low: Transamerica carries long-term care and older universal life liabilities whose reserve adequacy depends on morbidity, mortality, lapse and claim-cost assumptions that get revisited annually, and an adverse review can wipe out a year of earnings growth in one press release.

Read the full bull and bear case on AEG, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Aegon Ltd.'s investor relations page or your broker.

• Share price / market cap: ~$9.45, ~$14.2 billion on ~1.51 billion shares
• Revenue (TTM): ~$14.3 billion
• Net income (TTM): ~$1.08 billion, EPS ~$0.69
• P/E: ~13x trailing, ~9.5x forward
• Operating capital generation (FY2025): ~EUR 1.3 billion, above the ~EUR 1.2 billion target
• Dividend: ~EUR 0.40 per share for 2025 (~$0.47), roughly a ~4.7% trailing yield

Aegon reports in euros on a half-yearly calendar, so the trailing US-dollar figures above are converted and will not line up exactly with the company's own releases. The most recent full set is the second-half and full-year 2025 report published February 19, 2026, which showed an operating result of about EUR 1.7 billion (up 15 percent) and a net result of about EUR 980 million (up 45 percent). First-half 2026 results are scheduled for August 20, 2026, and the numbers above sit ahead of that print.

Other names that sit close to AEG: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get AEG exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so AEG sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AEG fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

AEG prices as a mid-single-digit-multiple life insurer paying out most of what it generates, with the redomiciliation to the US and the long-tail American life book deciding whether that discount narrows or persists.

Whether AEG is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AEG a buy or a sell?, and where the stock could go from here in the AEG stock forecast.

For income investors, whether AEG pays a dividend and how the payout looks is covered in does AEG pay a dividend? And to weigh AEG against a peer, read the full side-by-side comparisons: AEG vs MET and AEG vs PRU.